Barclays PLC Has $14.12 Million Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Barclays PLC trimmed its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 70.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 226,403 shares of the company's stock after selling 545,397 shares during the quarter. Barclays PLC owned approximately 0.67% of TransMedics Group worth $14,117,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Arizona State Retirement System lifted its holdings in TransMedics Group by 1.9% during the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock valued at $603,000 after purchasing an additional 184 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of TransMedics Group by 7.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock valued at $294,000 after purchasing an additional 317 shares during the period. Park Avenue Securities LLC boosted its holdings in shares of TransMedics Group by 3.8% during the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company's stock worth $548,000 after buying an additional 322 shares during the period. Alliancebernstein L.P. raised its holdings in TransMedics Group by 1.2% in the 4th quarter. Alliancebernstein L.P. now owns 40,572 shares of the company's stock valued at $2,530,000 after acquiring an additional 500 shares during the period. Finally, Atlas Capital Advisors Inc. acquired a new stake in TransMedics Group during the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Price Performance

Shares of TMDX stock traded down $3.05 during trading hours on Friday, reaching $91.13. The company's stock had a trading volume of 727,466 shares, compared to its average volume of 1,345,164. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The firm's 50 day simple moving average is $74.09 and its 200-day simple moving average is $78.54. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of 96.94 and a beta of 2.14.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TMDX shares. Canaccord Genuity Group restated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Wednesday. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.